Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments? Commentary

Nature Clinical Practice Oncology

Volumn 4, Issue 3, 2007, Pages 152-153

  Takimoto, Chris H ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; CYTOCHROME P450 2D6; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; ENDOXIFEN; NORTAMOXIFEN; PAROXETINE; TAMOXIFEN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG METABOLISM; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HOT FLUSH; HUMAN; PATIENT CODING; PATIENT SELECTION; PHARMACOGENETICS; PHENOTYPE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL TIME;

EID: 33847633415     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0716     Document Type: Editorial

References (3)

1. Steams V et al. (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95: 1758-1764
2. Goetz MP et al. (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23: 9312-9318
3. Jin Y et al. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97: 30-39